nach oben

Erschienen in:

01.03.2010 | Original Article

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

verfasst von: Gabriella Ferrandina, Valentina Mey, Sara Nannizzi, Simona Ricciardi, Marco Petrillo, Cristiano Ferlini, Romano Danesi, Giovanni Scambia, Mario Del Tacca

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gemcitabine (2′,2′-difluorodeoxycytidine) (GEM) is one of the most actively investigated drugs in ovarian cancer. Many molecular mechanisms have been proposed to be involved in GEM sensitivity/resistance including the equilibrative nucleoside transporter-1 (hENT1), the concentrative nucleoside transporter-1 (hCNT1), and deoxycytidine kinase (dCK). The expression of the ribonucleotide reductase regulatory subunits M1 (RRM1) and M2 (RRM2), and the catabolic enzymes 5′nucleotidase (5′NT), and cytidine deaminase (CDA) play also an important role. The aim of the study is to investigate the potential clinical role of hENT1, hCNT1, dCK, RRM1, RRM2, CDA, and 5′NT in a single institutional series of 25 primary ovarian carcinomas.

Methods

The expression levels of the target genes were assayed by means of real-time quantitative PCR. The clinical role of the expression levels of each parameter was analyzed by Kaplan and Meier method and the Cox’s proportional hazards model.

Results

hENT1, hCNT1, dCK, CDA, 5′NT, RRM1, and RRM2 gene expression was documented in all samples; undifferentiated and clear cell carcinoma exhibited higher levels of hENT1, dCK, 5′NT, and RRM1 compared to serous ovarian tumors. As of May 2009, the median follow-up was 32 months (range 10–80), and death of disease were observed in 17 cases (68.0%). A statistically significant direct association of RRM2 expression levels and the relative risk of death was observed (Χ ² = 8.18, P = 0.0043). Moreover, cases with high RRM2 expression had a shorter OS (median OS = 19 months) than cases with low RRM2 levels (median OS = 36 months) (P = 0.0506).

Conclusions

We first reported that the most relevant genes involved in gemcitabine metabolism are expressed in ovarian carcinoma, and might be associated with more aggressive histotypes. The assessment of the expression levels of RRM2 as marker of clinical outcome deserves further investigation in a larger series of ovarian cancer patients.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMed

Markman M (2008) Pharmaceutical management of ovarian cancer: current status. Drugs 68:771–789CrossRefPubMed

Vermorken JB (2008) Second-line randomized trials in epithelial ovarian cancer. Int J Gynecol Cancer 18(Suppl 1):59–66CrossRefPubMed

Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG158) and an update on GOG 182-ICON5. Int J Gynecol Cancer 13:735–740CrossRefPubMed

D’Agostino G, Amant F, Berteloot P, Scambia G, Vergote I (2003) Phase II study of gemcitabine in recurrent platinum- and paclitaxel resistant ovarian cancer. Gynecol Oncol 88:266–269CrossRefPubMed

Ferrandina G, Paris I, Ludovisi M, D’Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G (2005) Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol 98:267–273CrossRefPubMed

Jordheim LP, Dumontet C (2007) Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776:138–159PubMed

Kim MP, Gallick GE (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14:1284–1285CrossRefPubMed

Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A (2008) Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 76:322–329CrossRefPubMed

10.

Fan H, Huang A, Villegas C, Wright JA (1998) The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA 94:13181–13186CrossRef

11.

Gautam A, Li ZR, Begler G (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22:2135–2142CrossRefPubMed

12.

Fan H, Villegas C, Huang A, Wright JA (1998) The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58:1650–1653PubMed

13.

Zhou BS, Tsai R, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y (1998) Overexpression of the transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Exp Clin Met 16:43–49CrossRef

14.

Duxbury MS, Whang EE (2007) RRM2 induces NF-κB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun 354:190–196CrossRefPubMed

15.

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928–3935CrossRefPubMed

16.

Sebastiani Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12:2492–2497CrossRef

17.

Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij De, Cobelli O, Pece S, Del Tacca M, Danesi R (2006) In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 95:289–297CrossRefPubMed

18.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797–1803CrossRefPubMed

19.

Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355–1363CrossRefPubMed

20.

Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98:1710–1715CrossRefPubMed

21.

Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Del Tacca R, Danesi R (2007) Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacological Res 55:343–349CrossRef

22.

Chatterjee SK, Bhattacharya M, Barlow JJ (1981) Evaluation of 5′-nucleotidase as an enzyme marker in ovarian carcinoma. Cancer 47:2648–2653CrossRefPubMed

23.

Farré X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M (2004) Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112:959–966CrossRefPubMed

24.

Ferrandina G, Legge F, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Corrado G, Scambia G (2007) A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. Cancer Chemother Pharmacol 60:459–461CrossRefPubMed

25.

Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1:365–374PubMed

26.

Kaplan E, Meyer P (1958) Non parametric estimation from incomplete observations. J Am Statist Assoc 53:457–481CrossRef

27.

Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed

28.

Cox DR (1972) Regression models and life tables. J R Stat Soc 34:197–220

29.

Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, Agarwal RP (2005) Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem Pharmacol 70:426–432CrossRefPubMed

30.

Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349–4357PubMed

31.

Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R (2004) Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95:753–757CrossRefPubMed

32.

Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875–890CrossRefPubMed

33.

Heidel JD, Ching Liu JY, Yen Y, Zhou B, Heale BSE, Rossi JJ, Bartlett DW, Davis ME (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13:2207–2215CrossRefPubMed

34.

Cerqueira NM, Fernandes PA, Ramos MJ (2007) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Patents Anticancer Drug Discov 2:11–29CrossRef

35.

Chen S, Zhou B, He F, Yen Y (2000) Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense DNA. Antisense Nucleic Acid Drug Dev 10:111–116PubMed

36.

Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802–2811PubMed

37.

Lin ZP, Belcourt MF, Cory JG, Sartorelli AC (2004) Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(−/−) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 279:27030–27038CrossRefPubMed

38.

Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539–1548CrossRefPubMed

Titel: Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer
verfasst von: Gabriella Ferrandina
Valentina Mey
Sara Nannizzi
Simona Ricciardi
Marco Petrillo
Cristiano Ferlini
Romano Danesi
Giovanni Scambia
Mario Del Tacca
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1073-y

Springer Medizin

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer